Search Stage 1 Diagnostics, Inc. Products
Stage I Diagnostics, Inc. (Stage I) is a Delaware C-Corp founded in 2005 to commercialize a panel of novel diagnostic tests capable of detecting early stage ovarian cancer as well as other reproductive tract cancers such as prostrate cancer.
Early detection of ovarian cancer, which primarily affects postmenopausal women, could save up to 50,000 lives a year. Complimentary markers to CA125 are clearly needed to effectively monitor all ovarian cancer patients and to provide a panel of markers to diagnose early stage disease as well as offer opportunities for theraputic intervention in cancer patients.
To date, Stage I has produced serum based diagnostic tests for seven new markers. These seven markers, coupled with CA-125, comprise an initial diagnostic panel that has been verified for efficacy utilizing a limited set of serum samples. The complimentary tests include MMP-7, SCCE (KLK7), TADG-12 (TMPRSS3), TADG-14 (KLK8), TADG-15 (Matriptase), ALP (SLPI) and Hepsin for which Stage I holds composition of matter patents and/or use patents for cancer diagnosis.
Still Need More Help?
If you have sales questions relative to particular products or to your line of research,
please contact the CEDARLANE® sales department and have all of your questions answered
in a timely and professional manner.